- $SHWZ has gone from 0 dispensaries to 17 in 1 year.
- $SHWZ has gone from $10 million Revenue company to over $100 million Revenue company, and CEO has stated will be NET PROFITABLE in 2021.
- $SHWZ has only 42.3 million outstanding shares and trades with about a 28 million share float.
- $SHWZ CEO Justin Dye came from Albertsons, Inc., a multi-billion dollar grocery chain where he specialized in mergers and acquisitions.
- $SHWZ is located in Colorado, USA and is "rolling up" a vertical market there, with stated goals of many more acquisitions.
The later months of 2020 and the early months of 2021 were an outstanding time to be invested in Marijuana stocks.. Stocks like Tilray (TLRY) ran from lows around $2.50 to highs at $67.00. Almost every stock in the Marijuana sector saw gains, even the old sub-penny stock scam stocks. There were a couple of major factors, imo, that contributed to this boom. First, there was the COVID19 PANDEMIC, and the fact that liquor stores and Marijuana dispensaries were considered by most government bodies to be "essential businesses" and were allowed to remain open. As the pandemic year of 2020 progressed, it became obvious that marijuana sales were actually increasing dramatically, and several previously unprofitable marijuana companies, now are reporting profits, which has helped their stock prices immensely.
The second factor, was the fact that the USA Democratic Party won the presidency and vice presidency, and now has voting control of the US House of Represenatives and the US Senate. Vice President Kamala Harris co-authored the MORE act to decriminalize and regulate marijuana on the Federal level, and the belief that USA marijuana laws are going to be much more relaxed and friendly to marijuana, also sparked the rally.
That said, the rally seemed to get ahead of itself, and by February 2021, the sector has consolidated somewhat and some of the overheated names, such as Tilray, have seen 50% or more retraces of their gains...
So with that background, I now proceed to describe the subject of this blog, (OTCQX:SHWZ) OTCQX Schwazze (formerly operating as Medicine Man). So why is it URGENT that a marijuana investor investigate the Schwazze company? The answer is that I believe, that based on today's NEWS and closing stock price of $2.80/share that Schwazze is grossly undervalued compared to many other stocks in the marijuana industry.
I have looked, but I can't find another NET PROFITABLE, over 100 million in REVENUE, PUBLIC MARIJUANA COMPANY with a trading float of only 28 million shares, that has a share price below $3/share. And today, the company released the NEWS that it completed the acquisition of all the Colorado STARBUDS dispensaries, bringing its total to 17 dispensaries... $SHWZ also has a Grow Operation, and PurpleBees Manufacturing operation, thus being a complete "Seed to Sale" vertically integrated operation.
Now I'm not going to describe all the operations and people of Schwazze, but if you are interested, I highly encourage you to take a look at this information previously published on Seeking Alpha, as 99% of it is still accurate, and then you can see why some of us shareholders are excited to be acquiring shares at such a low price at this time...Medicine Man Technologies (SHWZ) Presents 2021 ICR Conference - SlideshowAt (OTCMKTS:SHWZ) | Seeking Alpha
So with that said, I'll end this article. I believe the Democrats will finish the Covid Stimulus Bill soon, and the focus will turn back to Marijuana and Decriminalization and fair taxation and banking for the industry, and the "correction" we have been in will end, and the rally in good marijuana companies will resume... Thus the urgency... Good luck in your investing, all.
Analyst's Disclosure: I am/we are long SHWZ.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.